4BIO Partners LLP
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.
4BIO’s objective is to invest in, support, and grow early-stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.
The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.
4BIO invests into advanced therapies companies across private and public markets, out of two separate funds. The firm has recently announced the first close of its Ventures II Fund at US$50 million.
For more information, please visit www.4biocapital.com
